OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS OPEN END TURBO PUT-OPTIONSSCHEIN MIT SL - VERTEX PHARMACEUTICALS Share Price
Certificat
DE000SU6Y2H1
| Market Closed - Deutsche Boerse AG 20:46:06 16/05/2024 BST | ||
| 20.9 EUR | -1.23% |
|
| Current month | -18.23% | ||
| 1 month | -18.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 16/05/24 | 20.9 | -1.23% |
| 15/05/24 | 21.16 | -4.38% |
| 14/05/24 | 22.13 | +0.45% |
| 13/05/24 | 22.03 | -2.91% |
| 10/05/24 | 22.69 | -1.00% |
Delayed Quote Deutsche Boerse AG
Last update May 16, 2024 at 08:46 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Société Générale
|
| WKN | SU6Y2H |
| ISIN | DE000SU6Y2H1 |
| Date issued | 15/01/2024 |
| Strike | 667.6 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.57 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 25.83 € |
|---|---|
| Lowest since issue | 20.12 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
440.6
USD
Average target price
462.6
USD
Spread / Average Target
+4.97%
- Stock Market
- Certificates
- Certificat
